Elicio Therapeutics
Elicio Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of amphiphile immunotherapies aimed at treating aggressive cancers. The company leverages its proprietary Amphiphile platform to deliver immunogens directly to the lymphatic system, enhancing the immune response and improving the body’s ability to fight cancer. Elicio's key products include ELI-002, an amphiphile vaccine targeting KRAS gene mutations to prevent recurrence in pancreatic, colorectal, and lung cancers, and ELI-001, which is designed for HPV-driven head and neck cancers. Elicio Therapeutics was founded in 2011 and was previously known as Vedantra Pharmaceuticals before rebranding in 2019. The company focuses on creating innovative immunotherapies for patients with limited treatment options and challenging cancer types.
Top Stages
1 past transactions
Angion
Acquisition in 2023
Angion Biomedica Corp. is a clinical-stage biopharmaceutical company dedicated to discovering and developing small molecule therapeutics aimed at treating acute organ injuries and fibrotic diseases, particularly focusing on renal conditions. The company is advancing several product candidates, including BB3, which is undergoing phase 3 trials for delayed graft function following kidney transplants and phase 2 trials for acute kidney injury related to open-heart surgery. Another key candidate, ANG-3070, is an orally bioavailable fibrokinase inhibitor designed for chronic kidney disease and polycystic kidney disease. Additionally, Angion is exploring other compounds targeting renal disease and fibrosis, such as ANG-3586 and ANG-4021. Founded in 1998, Angion is headquartered in San Francisco, California, with research facilities in New York and clinical operations in Boston.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.